Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-06-14
2010-10-19
Fetterolf, Brandon J (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S358000
Reexamination Certificate
active
07816358
ABSTRACT:
Pharmaceutical formulations comprising N,N′disubstituted piperazine compounds and related methods of treatment using these formulations.
REFERENCES:
patent: 3716538 (1973-02-01), Schut
patent: 4203986 (1980-05-01), Joullie et al.
patent: 7030276 (2006-04-01), Finkam et al.
patent: 2003/0008859 (2003-01-01), Sundermann et al.
patent: 19963175 (2001-07-01), None
patent: WO03/051855 (2003-06-01), None
patent: WO 2004/020390 (2004-03-01), None
Mukaiyama ‘From a synthetic organic chemist’ Pure and Applied Chemistry, 69(2), p. 257-258, 1997.
Chiang et al ‘Intraocular Pressure Lower Effects of Novel Arylpiperazine Derivatives’ Journal of Ocular Pharmacology, 14(4), p. 313-322, 1998.
Patani et al ‘Bioisosterism: A rational approach in drug design’ Chemistry Reviews, vol. 96, p. 3147-3176, 1996.
Cannon, J.G., Chapter Nineteen in Burger's Medicinal Chemistry and Drug Discovery Volume I: Principles and Practice Wiley Interscience, Fifth Edition, p. 783-802 and 784, 1995.
Horig et al, “From Bench to clinic and back: Perspective on the 1stIQPC Tranlational Research conference” Journal of Translational Medicine, 2(44), p. 1-8, 2004.
Schafer et al ‘Failure is an option: learning from unsuccessful proof-of-concept trials’ Drug Discovery Today, 13(21/22), p. 913-916, 2008.
Justin S. Bryans et al., “3-Substituted GABA Analogs with Central Nervous System Activity: A Review”, Med. Res. Rev., 1999, pp. 149-177, 19, John Wiley & Sons, Inc.
Mark Schrope, “The Coxsackie Kicker”, News in Brief, Modern Drug Discovery, Sep. 2000, p. 11, 2000 American Chemical Society.
Albert Lespagnol et al., “Chemical and Pharmacodynamic Study of Benzylacetophenone Derivatives”, 1972, p. 293-239, Lab Pharmacodyn, Chim. Ther., France.
Milka Nikolova et al., “Synthesis and Pharmacological Screening of a Group of Piperazine Derivatives Analgesic Activity”, IL Farmaco, 1993, pp. 459-472, 48, 4, XP-000617338.
Masahisa Hashimoto et al., “Metabolism of a New Analgesic Agent,di-erythro-1-Phenyl-2-(o-Chlorophenyl)-2-[4-(p-Methoxybenzyl)-1-Piperazinyl]Ethanol Dihydrochloride, in Rats”, Drug Metabolism and Disposition, 1979, pp. 435-441, vol. 7, No. 6, The American Society of Pharmacology and Experiential Therapeutics, USA, XP-973712A.
Jean C. Cazin et al., “Pharmacological Activity of Aminoalcohols Derivated from Benzylacetophenone”, Eur. J. Med. Chem.—Chim. Ther., 1974, pp. 408-415, 9, 4, France.
M. Boniface, “Computer Calculation of Effective Dose Using the Method of Probits”, 1972, Abstract, Bull. Soc. Pharm., 4, France.
Buschmann Helmut
Chizh Boris
Haubrand Michael
Maul Corinna
Sundermann Bernd
Crowell & Moring LLP
Fetterolf Brandon J
Gruenenthal GmbH
Stone Christopher R
LandOfFree
Pharmaceutical formulations comprising... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical formulations comprising..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical formulations comprising... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4230870